A randomized Controlled trial comparison of enoxaparin 40 mg versus 60 mg dosage for venous thromboembolism prophylaxis in bariatric surgery

Phase 1

• Conditions: Morbid obesity Thromboembolism Pulmonary embolism Deep vein thrombosis; venous thromboembolism; prophylaxis; bariatric surgery; morbid obesity; enoxaparin; Anti- factor Xa level

• Registration Number: TCTR20201016001
• Lead Sponsor: none

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-16
• Study Completion: 2021-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Patient at age between 15 years and 60 years, BMI equal or more than 32.5 kg/m2 with one of co-morbid diseases such as diabetes mellitus, cardiac disease, hypertension, Obstructive sleep apnea, weight bearing joint pain or the patients that have BMI equal or more than 37.5 kg/m2.

Exclusion Criteria

patient with VTE or prior using anticoagulant and the patients with the severe medical condition which cannot go on operation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The percentage of target level achievement in both groups 1 year Percentage of achievement target level

Secondary Outcome Measures

Name	Time	Method
The mean anti-factor Xa levels in both groups 1 year mean as IU/ml